Chongqing Zhifei Biological Products (300122.SZ): DeGu Insulin Injection has applied for production registration and has been accepted.

Chongqing Zhifei Biological Products (300122.SZ) announced that the production registration application for Degutu insulin injection, developed by its holding subsidiary Chongqing Cheng'an Biological Pharmaceutical Co., Ltd. (referred to as "Cheng'an Biological"), has obtained the "Acceptance Notice" issued by the National Medical Products Administration. The announcement shows that Degutu insulin is a long-acting insulin analog. With its unique molecular structure and mechanism of action, it can form a soluble hexamer storage pool under the skin, achieving a stable, sustained, and slow release of insulin. The duration of action is significantly extended, with the advantages of stable hypoglycemic effect, low blood sugar variability, low risk of hypoglycemia, good safety, and flexible dosing time. It is suitable for the treatment of type 2 diabetes in adults with once-daily subcutaneous injection.